Fox Chase Cancer Center News

PHILADELPHIA (March 6, 2019) — New research from scientists at Fox Chase Cancer Center suggests the immune gene ThPOK has remained similar for more than 165 million years.

PHILADELPHIA (March 5, 2019) – Men at high-risk for prostate cancer are the most likely to undergo routine prostate cancer screening, and now, scientists at Fox Chase Cancer Center have developed a method of preparatory counseling that could better help to prepare these men for the psychological impact of their screening results.

PHILADELPHIA (March 1, 2019) —Patients, survivors, caregivers and advocates join together this March for National Colorectal Cancer Awareness Month. 

The TAILORx trial found that thousands of women with a certain type of early-stage hormone-positive, HER-2 negative breast cancer did just as well with hormone therapy alone. 

SAN MATEO, CA, February 19, 2019 — Fox Chase Cancer Center and MORE Health, a global healthcare company, announced a cutting-edge partnership that gives patients from across the world access to the nationally ranked physicians of Fox Chase Cancer Center through MORE Health’s Physician Collaboration Platform™.

PHILADELPHIA (February 18, 2019) — John Krais, PhD, a postdoctoral researcher at Fox Chase Cancer Center, recently received a two-year, $75,000 grant from the Ovarian Cancer Research Alliance (OCRA) for his investigation into DNA repair processes in BRCA1 mutant cancers.

PHILADELPHIA (February 15, 2019) – A board-certified psychiatrist, Suzanne Doubrava, MD, has done extensive research on the effects of long-term psychodynamic psychotherapy for end-stage cancer patients. She comes to Fox Chase after several years in private practice.

PHILADELPHIA (February 13, 2019) — Fox Chase Cancer Center researchers have published a groundbreaking study that describes for the first time the mechanisms of how the amount of amino acid phenylalanine (Phe) is controlled in blood. Accumulation of Phe can cause phenylketonuria (PKU), a rare genetic condition that can result in permanent neurological damage as well as behavioral abnormalities if not properly managed.